Enzon appoints Stephen T. Wills to board; forms special committee to evaluate Viskase proposal

Viskase Holdings, Inc.

Board increased to four; Stephen T. Wills appointed as director effective January 7, 2025.
Special committee of independent directors (Randolph Read chair, Wills member) formed to evaluate any transaction proposed by Viskase Companies.
No terms of the proposal have been received; no decision made and no assurance any transaction will result.
Wills is CFO/COO of Palatin Technologies, CPA, with board experience at MediWound and other biopharma firms.

item 5.02 item 8.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Stephen T. Wills

Director

ENZN · Viskase Holdings, Inc.

Effective: 2025-01-07
Filed: January 10, 2025, 6:59 PM ET

On January 7, 2025, the Board of Directors (the “Board”) of Enzon Pharmaceuticals, Inc. (the “Company”) approved an increase in the number of directors on the Board to four and appointed Stephen T. Wills as a director, effective immediately.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Stephen T. Wills was appointed as Director at Viskase Holdings, Inc..

Action: appointed
Role: Director

Exact text from the filing

On January 7, 2025, the Board of Directors (the “Board”) of Enzon Pharmaceuticals, Inc. (the “Company”) approved an increase in the number of directors on the Board to four and appointed Stephen T. Wills as a director, effective immediately.

View on SEC.gov

Viskase Holdings, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-25-002591

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.